AcquisitionsJun 15, 2026, 09:36 AM
InterCure Closes Botanico Acquisition Tranche, Reviews US Cannabis Opportunities
AI Summary
InterCure Ltd. announced the successful completion of the first tranche of its acquisition of Botanico Ltd., an Israeli cannabis technology and brand company. This acquisition strengthens InterCure's portfolio with exclusive rights to U.S. cannabis genetics, brands, and advanced AI-driven technologies. Concurrently, the company has initiated a strategic review of potential opportunities within regulated U.S. medical cannabis markets following the recent federal rescheduling of medical cannabis. InterCure also reported growing demand and initial revenues from the German medical cannabis market, supporting its international expansion strategy.
Key Highlights
- Completed the first tranche (50%) of the Botanico Ltd. acquisition.
- Issued 2,471,061 ordinary shares for the initial closing of the Botanico transaction.
- Will issue an additional 2,470,073 ordinary shares upon satisfaction of remaining conditions.
- Initiated a strategic review of U.S. medical cannabis opportunities following federal rescheduling to Schedule III.
- Botanico acquisition provides exclusive rights to U.S. cannabis genetics, premium brands, and AI-driven technologies.
- Reported first meaningful revenues from the rapidly growing German medical cannabis market.
- Appointed a German management and sales team, anticipating multiple product launches in H2.
Price Impact
More from INCR